Condition: Advanced Solid Tumor · Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
This description comes directly from the study's public registry record.
Xiaorong Dong, PhD · 13986252286 · xhzzdxr@126.com
Always discuss trial participation with your own doctor first.
| Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05367778